print

David G. Hicks, M.D.

Professor of Pathology and Laboratory Medicine

Surgical Pathology
Bone, Soft Tissue and Breast Diseases

URMC Labs
601 Elmwood Ave., Rm G-5320A
Rochester, NY 14642-8626
Tel: (585) 275-3191
Fax: (585) 273-3637

David_Hicks@urmc.rochester.edu
send e-mail

Director of Surgical Pathology. Dr. Hicks' innovative approaches to improving efficiency and quality in surgical pathology have been highlighted in publications and invited lectures sponsored by national pathology organizations. His organizational interests are in the development of a subspecialty-based surgical pathology system, combining disease-specific diagnostic and prognostic expertise with translational research based on organ systems and disease categories.

Qualifications

M.D. University of Rochester, 1984
Intern, Medicine, Hospital of the University of Pennsylvania, 1984-85
Resident, Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, 1985-89
Board Certification, American Board of Pathology (Anatomic Pathology), 1990

Professional Activities

Stowell-Orbison Award, US and Canadian Academy of Pathology, 1989
Arthur Purdy Stout Award, US and Canadian Academic of Pathology, 1991
Kappa Delta Elizabeth Winston Lanier Award for Outstanding Orthopaedic Research, American Academy of Orthopaedic Surgeons, 1995
Andrew W. Mellon Dean's Teaching Scholar, University of Rochester, 1996-99
John Beach Hazard Distinguished Teaching Award, Cleveland Clinic Foundation, 2002
Dr. Edith E. Sproul Teaching Award, Roswell Park Cancer Institute, 2006

Editorial Board, Archive of Pathology and Laboratory Medicine
Editorial Board, Journal of Bone and Joint Survery

Research Overview

Dr. Hicks' first research interest was in bone pathology. He received NIH funding to study the effects of lead on the epiphyseal plate, and collaborated on related studies with faculty in the Department of Orthopaedics at the University of Rochester. He published extensively on metabolic and neoplastic bone disorders. While Director of Surgical Pathology and Co-director of the Morphologic Molecular Pathology translation research resource at the Cleveland Clinic, he expanded his interests in breast pathology, with particular focus on prognostic molecular markers in breast cancer and developmetn of advanced tissue-based diagnostic techniques.

Publications

Sossey-Alaoui K, Safina A, Li X, Vaughan MM, Hicks DG, Bakin AV, Cowell JK. Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cells. Am J Pathol. 2007 Jun;170(6):2112-21.

Goldstein NS, Hewitt SM, Taylor CR, Yaziji H, Hicks DG; Members of Ad-Hoc Committee On Immunohistochemistry Standardization. Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):124-33.

Lietman SA, Prescott NL, Hicks DG, Westra WH, Levine MA. SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism. Clin Orthop Relat Res. 2007 Jun;459:22-7.

Tubbs RR, Swain E, Pettay JD, Hicks DG. An approach to the validation of novel molecular markers of breast cancer via TMA-based FISH scanning. J Mol Histol. 2007 May;38(2):141-50.

Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S, Williams T, Short S, Pettay J, Nagle RB, Dabbs DJ, Scott KM, Brown RW, Grogan T, Roche PC, Tubbs RR. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11,
fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):94-102.

Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS, Li F. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor
formation in vivo. Breast Cancer Res Treat. 2007 Mar;102(1):19-30. Epub 2006 Aug 8.

Short SM, Yoder BJ, Tarr SM, Prescott NL, Laniauskas S, Coleman KA, Downs-Kelly E, Pettay JD, Choueiri TK, Crowe JP, Tubbs RR, Budd TG, Hicks DG. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to
chemotherapy: a retrospective immunohistochemical study. Breast J. 2007 Mar-Apr;13(2):130-9.

Tubbs RR, Pettay JD, Swain E, Roche PC, Powell W, Hicks DG, Grogan T. Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility study. Appl Immunohistochem Mol Morphol. 2006 Dec;14(4):436-40.

Hicks DG, Yoder BJ, Short S, Tarr S, Prescott N, Crowe JP, Dawson AE, Budd GT, Sizemore S, Cicek M, Choueiri TK, Tubbs RR, Gaile D, Nowak N, Accavitti-Loper MA, Frost AR, Welch DR, Casey G. Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res. 2006 Nov 15;12(22):6702-8.

Shao YY, Wang L, Hicks DG, Ballock RT. Analysis of gene expression in mineralized skeletal tissues by laser capture microdissection and RT-PCR. Lab Invest. 2006 Oct;86(10):1089-95.

Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Budd GT, Tubbs RR, Casey G, Weil RJ. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006 Sep;30(9):1097-104.

Crowe JP, Patrick RJ, Rybicki LA, Budd GT, Escobar PF, Tubbs RR, Hicks DG. HER2 status in bilateral breast cancer. Int J Fertil Womens Med. 2006 Sep-Oct;51(5):219-23.

Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, Yoder BJ, Budd GT, Nielsen TO, Hicks DG, Estopinal NC, Ross DT. Novel prognostic immunohistochemical biomarker panel for estrogen
receptor-positive breast cancer. J Clin Oncol. 2006 Jul 1;24(19):3039-47.

Tubbs R, Pettay J, Powell R, Hicks DG, Roche P, Powell W, Grogan T, Hainfeld JF. High-resolution immunophenotyping of subcellular compartments in tissue microarrays by enzyme metallography. Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):371-5.

Hicks DG, Dawson A, Mattingly S, Crowe JP. The unmet clinical need for new molecular genetic markers in the prognosis and therapeutic management of breast cancer. Arch Pathol Lab Med. 2005 Nov;129(11):1372-4.

Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, Roche P, Hicks DG. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 2005 Sep;29(9):1221-7.

Shao YY, Wang L, Hicks DG, Tarr S, Ballock RT. Expression and activation of peroxisome proliferator-activated receptors in growth plate chondrocytes. J Orthop Res. 2005 Sep;23(5):1139-45.

Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, Skacel M, Crowe JP, Budd GT, Tubbs RR. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol. 2005 Apr;36(4):348-56.

Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol. 2005 Mar;36(3):250-61. Review.

Hicks DG, Longoria G, Pettay J, Grogan T, Tarr S, Tubbs R. In situ hybridization in the pathology laboratory: general principles, automation, and emerging research applications for tissue-based studies of gene expression. J Mol Histol. 2004 Aug;35(6):595-601. Review.